Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Genfit

- PMLiVE

Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis

The drug already holds approvals to treat primary biliary cholangitis, another rare liver disease

- PMLiVE

Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis

The life-long condition affects approximately 1,900 people in Scotland

- PMLiVE

Ipsen shares positive three-year results for Iqirvo in primary biliary cholangitis

The rare liver disease affects approximately 100,000 people in the US

- PMLiVE

Ipsen’s Iqirvo recommended by NICE to treat rare liver disease primary biliary cholangitis

The disease affects approximately 25,000 people in the UK, the majority of whom are women

- PMLiVE

Ipsen’s Iqirvo receives FDA approval to treat adults with primary biliary cholangitis

The rare cholestatic liver disease currently affects approximately 100,000 people in the US

- PMLiVE

Honoring Educational Partners at ACG

The recent ACG conference was an opportunity for members of the Medscape team to shine a light on their educational partners and honor them for their exceptional work.On October 21,...

Medscape Education

International NASH Day 2023

Shari Dermer, PhD of Medscape Education, hosted Michael Betel, Founder and President of Fatty Liver Alliance, in an engaging conversation around the importance of NASH awareness, diagnosis, and prognosis. Listen...

Medscape Education

- PMLiVE

How the WHO hepatitis strategy measures up in the field

With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...

Avalere Health

- PMLiVE

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

The two companies first announced their NASH collaboration in 2019

Podcast

Living With Chronic Illness (Series one)

Inizio

- PMLiVE

Merck enters agreement with Hanmi for investigational NASH drug

Licensing agreement includes $10m upfront payment

- PMLiVE

Genfit scraps phase 3 trial of experimental NASH drug

Drug failed to meet primary endpoint in interim analysis

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links